Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase III for Metastatic Prostate Cancer. According to GlobalData, Phase III ...

Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to ...

Kevin O'Marah, the chief research officer and co-founder of Zero100, a community research platform working towards zero carbon, sheds more light on how supply chains are likely to be impacted by ...

"While individual building blocks to power decentralized AI on the blockchain are available, they are mostly fragmented across platforms and chains," said Han Jin, CEO at Bluwhale. "Our L3 in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

UBS is a global firm providing financial services to private, corporate and institutional clients. We are present in all major financial centers and have offices in over 50 countries. In Luxembourg, ...

for prostate cancer and Novartis's Lutathera (lutetium Lu 177 dotatate) for neuroendocrine tumours (NETs), which delivers beta radiation. Ratio's Trillium platform uses an albumin carrier to ...

[37] Recently, three complement-regulatory proteins, decay-accelerating factor ... [22,25,26] Proteasomal subunits ζ-chain and component C2 of proteasome, sperm membrane proteins Antisperm ...